In the context of AML, several clinical studies have shown that bortezomib has potent anti-neoplastic activity, and the mechanisms include induction of apoptosis and transcriptional inactivation of several important AML-drivers such as DNA methyltransferases (DNMTs) and receptor tyrosine kinases (RTKs) [29, 38, 75, 76]. Here, NTRK1 is linked to acute myeloid leukemia.